Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BST-236 monotherapy in adults with relapsed or refractory AML or higher-risk MDS unfit for intensive chemotherapy
2020-003400-13Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aspacytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Started Nov 2020; status: completed.
02
Drugs
aspacytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-003400-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003400-13.